PCV61 Pharmacoeconomic Evaluation of Olmesartan, Losartan and Valsartan in Treatment of Essential Arterial Hypertension  by Gorokhova, S.G. & Ryazhenov, V.V.
PCV59
WHERE DID THE TIME GO?: TEMPORAL UNCERTAINTY IN COST-
EFFECTIVENESS DECISION MODELS
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OBJECTIVES: Since the required time horizon in a cost effectiveness decision
model often exceeds the evidence time horizon, numerous temporal uncertainties
arise regarding model parameters and structures. The objective of this study is to
demonstrate, through a motivating example: (i) why temporal uncertainty ought to
be addressed more thoroughly than it has been to date; (ii) how this uncertainty
might be expressed in decision models; and (iii) the consequences for the cost-
effectiveness results when temporal uncertainty is incorporated into the analysis.
METHODS: Taking the example of a decision model seeking to estimate the cost-
effectiveness of an early interventional strategy for patients with non-ST-elevation
acute coronary syndrome, we firstly highlight the model components that are ex-
posed to temporal uncertainty. Focusing on two key model parameters, we explore
the extent to which the existing short-term evidence could reasonably be extrap-
olated over time. We then suggest a means to quantitatively convey the temporal
uncertainty pertaining to these parameters within the model. RESULTS: Temporal
uncertainty is shown to have a significant impact on the cost-effectiveness results.
Value-of-Information analysis (specifically population EVPPI) suggests that for this
example, it may have been more cost-effective to delay adoption recommendation
until further evidence on the temporal behaviour of parameters was collected.
CONCLUSIONS: Temporal uncertainty, though rarely formally modelled, is a sig-
nificant characteristic of cost-effectiveness decision models. It is possible and de-
sirable to express temporal uncertainty within a decision model, as the complete
model may show that it is more cost-effective to collect further information on the
temporal behaviour of model parameters before issuing an adoption recommen-
dation.
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COST EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR PREVENTION OF
STROKE AND SYSTEMIC EMBOLISM IN NONVALVULAR ATRIAL FIBRILLATION
PATIENTS IN THE TURKISH HEALTH CARE SETTING
Kececioglu S, Ulus P, Cukadar F
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OBJECTIVES: To investigate the cost-effectiveness of dabigatran etexilate (dabiga-
tran 150MG) in the Turkish health care setting. METHODS: A model was con-
structed to assess the cost-effectiveness of dabigatran versus warfarin. Direct cost
of events (stroke, intracranial bleeding), physician visits, INR tests, medication and
patients’ hospital transfers were considered. Outcome measure is defined as the
total number of events prevented per year for a population of 1000 patients.
RESULTS: For a cohort of 1,000 patients, total cost of stroke in the warfarin arm was
468,672 TL/year and in the dabigatran arm 322,212 TL/year. Cost for intracranial
bleeding events was 234,336 TL/year and 87,876 TL/year for warfarin and dabiga-
tran, respectively. Total treatment cost in the warfarin arm was 1,395,693 TL/ year
and in the dabigatran arm 1,654,728 TL/ year. The ICER for dabigatran was 25,903
TL/stroke prevented (Cost per stroke event is given as 29.292 TL in current the
Turkish health care setting). CONCLUSIONS: A major limitation of this analysis is
that it doesn’t account for disability costs, which are other major direct costs of the
Turkish Social Security Institution. According to the World Health Organization, for
counties where a willingness to pay threshold for ICERs doesn’t exist, such as in
Turkey, ICERs remaining below 1-3 times of the GDP per capita per unit of health
gain are deemed acceptable. Dabigatran can be considered cost-effective with an
ICER per stroke avoided below the GDP per capita (31,280 TL estimated for 2012)
when compared to current standard of care in Turkey, which is warfarin.
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OBJECTIVES: Olmesartan medoxomil is one of the latest angiotensin II receptor
blockers (ARB) approved for use in the Russian Federation. The objective was to
assess cost-effectiveness of olmesartan compared with losartan and valsartan in
adult patients with mild and moderate essential arterial hypertension. METHODS:
The study was performed by modeling and cost-effectiveness analyses. We have
also assessed cost-effectiveness ratio (CER) growth rate, which represents the rel-
ative rate of change in value for the analyzed periods. Analyzed costs included
brand drugs only. Efficacy data were obtained from a head-to-head clinical trial, in
which office blood pressure rate, number of patients with mild and moderate ar-
terial hypertension achieving target blood pressure in weeks 4, 8, and 12 were taken
into account. Patients with diabetes mellitus and chronic renal failure were ana-
lyzed separately. The time horizon of the analysis was 12 weeks. Pairwise compar-
ison of costs, CER, CEAincr and CER growth rate were performed separately for
olmesartan vs. losartan, and olmesartan vs. valsartan. RESULTS: Treatment with
olmesartan provides more clinical effect for less costs and demonstrates better
cost-effectiveness ratio than losartan or valsartan in terms of target BP after 12
weeks. In both pairs, CER growth rate was minimal in case of olmesartan; this
reflects the dynamics of this value during treatment. Similar results were obtained
for comparable ARBs in patients with diabetes mellitus and renal failure.
CONCLUSIONS: Cost-effectiveness analysis shows that treatment of mild arterial
hypertension with olmesartan is more appropriate from the pharmacoeconomic
point of view than losartan and valsartan, both in general group and in patients
with diabetes mellitus and renal failure.
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OBJECTIVES: To evaluate the economic feasibility of using Hypoxenum in compar-
ison to not administering it, in the complex treatment of angina pectoris.
METHODS: A randomized prospective controlled study on typical practice of 200
patients who received comprehensive treatment of angina pectoris with or without
Hypoxenum, was performed to assess direct medical costs and cost effectiveness
ratio. RESULTS: Overall cost of treatment of one patient with angina pectoris
within 15 days in the hospital with Hypoxenum in the combined therapy was 5
968.94 rubles. The total cost of treatment of one patient in group of typical treat-
ment of angina pectoris was 5 294.10 rubles. As the criteria of the effectiveness of
treatment were taken: indicators of performed work, threshold power, exercise
tolerance test. At the end indicators of the Hypoxenum group and the typical
practice group were: work performed: increased of 25.9 kJ and 15.1 kJ, respectively
(differences were significant, p0.05), the threshold power was 25.5 Watt and 13,2
Watt, respectively. Increased exercise tolerance was observed in 49% of patients in
the Hypoxenum group and in 28% of patients in the control group. The cost- effec-
tiveness ratio for the criterion of completed work was 230.4 rubles and 350.6 rubles,
for threshold power - 234.07. and 401.06 rubles, for increasing of exercise tolerance
- 12 181.51 rubles and 18 907.50 rubles for Hypoxenum and typical practice,
respectively. CONCLUSIONS: The cost-effectiveness study on the dynamics of tol-
erance of exercise compared to typical practice, revealed that treatment of angina
pectoris, with Hypoxenum is a clinically and economically feasible.
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COST-EFFECTIVENESS OF TICAGRELOR IN THE MANAGEMENT OF ACUTE
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OBJECTIVES: A randomized phase-III clinical trial (PLATO) showed that a 1-year
dual antiplatelet treatment with ticagrelor and aspirin (ASA) reduced the compos-
ite endpoint of cardiovascular death, myocardial infarction (MI), and stroke with-
out an increase in major bleedings compared to the combination clopidogrel-ASA
in patients with acute coronary syndromes (ACS). Using a model based on the
PLATO outcomes, we assessed the cost-effectiveness of ticagrelor-ASA vs. clopi-
dogrel-ASA in ACS patients in Belgium. METHODS: The model developed in Tree-
Age combined a decision tree for the first year of treatment and a Markov model
with a lifelong time horizon using 1 year cycles. First year probabilities of events
(cardiovascular death, MI, strokes, bleedings) were derived from the PLATO study.
In subsequent years, transition probabilities between health states (event-free,
post-MI, post-stroke, death) were obtained from a previously published HTA-
model on clopidogrel-ASA in ACS. Utility data was provided by literature. Cost data
was obtained from published articles and from the IMS Hospital Disease Database,.
The incremental cost-effectiveness ratio (ICER) of ticagrelor vs. generic clopidogrel
was calculated in terms of cost per quality-adjusted life-year (QALY) gained over a
lifetime horizon from the Belgian payer perspective and evaluated against the
lower WHO threshold based on 1 time the Gross Domestic Product for Belgium
(around 30,000€/QALY). Annual discounting rates of 3% and 1.5% were applied on
costs and effects respectively. RESULTS: Ticagrelor-ASA was associated with an
incremental cost of €816.9 and 0.079 added QALY’s (primarily driven by a reduction
in MI and mortality). The ICER was 10,316€/QALY. The cost per life year gained was
6,965€. The ICERs were consistent in subgroups of patients treated invasively or
not. Probabilistic sensitivity analysis showed that the ICER remained below
30,000€/QALY in 98.8% of cases (also in subgroups). CONCLUSIONS:Dual antiplate-
let treatment with ticagrelor-ASA can be considered cost-effective compared to
clopidogrel-ASA.
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OBJECTIVES: Adding omega-3 acid ethyl esters 90 (O-3EE) to standard therapies in
secondary prevention after post myocardial infarction (MI) significantly reduces
sudden death. This study evaluates the cost-effectiveness of adding 1g O-3EE to
current secondary prevention treatment after acute MI in the Irish and Estonian
public health care systems. METHODS: Based on GISSI-Prevenzione trial outcomes
(MI, stroke, revascularisation rate, mortality), two models for Ireland and Estonia
were developed, using a lifetime and 3.5-years (GISSI-Prevenzione trial duration)
time horizons with 1-year cycles. Local event costs were based on AR-DRGs (Ire-
land) and NordDRGs tariffs (Estonia). Life expectancy data (12.9 years) for survivors
of cardiac disease (15,590 cases) were obtained from the Saskatchewan database
and country-adjusted. Annual discounting of 4% (Ireland) and 5% (Estonia) was
applied on outcomes and costs. Incremental cost (€) per life year gained (LYG) and
Quality of Adjusted Life years Gained (QALYG) were calculated from the public
payer perspective. RESULTS: Lifelong treatment with O-3EE yielded 0.26 LYG, 0.19
QALYG (Ireland) and 0.24 LYG (Estonia) with an additional total direct cost of €1,624
(Ireland) and €1,218 (Estonia) resulting in an incremental cost-effectiveness ratio
(ICER) of €6,223/LYG and €8,210/QALYG (Ireland) and €5,079/LYG (Estonia). Respec-
tive ICERs at 3.5-years were €18,686/LYG, €23,527/QALYG for Ireland and €28,797/
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